Brainstorm Cell Therapeutics (NASDAQ:BCLI) Raised to “Sell” at Wall Street Zen

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Brainstorm Cell Therapeutics Stock Down 6.8%

NASDAQ:BCLI opened at $1.10 on Friday. The firm has a market capitalization of $8.73 million, a price-to-earnings ratio of -0.23 and a beta of 0.24. Brainstorm Cell Therapeutics has a twelve month low of $0.72 and a twelve month high of $6.94. The stock’s 50 day moving average price is $1.10 and its two-hundred day moving average price is $1.54.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.07). As a group, analysts anticipate that Brainstorm Cell Therapeutics will post -3.01 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 690,666 shares of the biotechnology company’s stock, valued at approximately $870,000. Armistice Capital LLC owned about 10.59% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.